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Abstract 
The incidence of leukaemia in South Africa is 2.5 per 100 000 and has increased due to HIV. 
Accurate and timeous diagnosis of leukaemia directly impacts success of patient treatment and 
consequent survival. Usually the Full Blood count (FBC), white blood cell (WBC) differential 
count and review of the peripheral blood smear alerts the clinician to the possibility of 
leukaemia. However the number of qualified and skilled technologists in peripheral and 
central laboratories is on a continual decline making the performance of the critical function of 
peripheral blood review a challenge.  
 
The Advia 2120 haematology analyser performs a WBC and differential count using 
principles of flow cytometry and the cytograms generated can be used to classify 
haematological malignancies through the Peroxidase and nuclear density analysis (PANDA) 
classification system. The presence of myeloperoxidase (MPO) activity in 3% or more 
leukaemic blasts confirms acute myeloid leukaemia, and enzyme activity can be detected by 
immunophenotypic analysis or conventional cytochemistry .  Research on the comparison of 
the Advia 2120 and manual morphologic assessment in the classification of leukaemias is 
limited in the South African setting, where leukaemia often coincides with infection. The aim 
of this study was to determine if the FBC, differential count and cytogram assessment by the 
Advia 2120 using the PANDA classification is as reliable as morphologic assessment in the 
initial classification of haematological malignancies from peripheral blood samples when 
using flow cytometry as the gold standard.. 
 
150 cases of confirmed leukaemia were collected. The diagnosis obtained from either PANDA 
analysis and/or morphological assessment was compared to the diagnosis obtained by 
immunophenotypic analysis. Secondly, the MPO activity obtained  by the Advia peroxidase 
cytogram was compared to the MPO obtained by conventional methods of immunophenotypic 
analysis and/or cytochemistry.  
 
Using the PANDA analysis system, only  48% (72/150) of cases overall were accurately 
classified. The inaccuracy was 9.3% (14/150) and 42.7% of cases could not be classified. The 
positive predictive value (PPV) was 88%. The most significant finding was all of the acute 
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promyelocytic leukaemia (APL) cases (8/8) had a distinct pattern and were accurately 
classified on cytogram analysis alone. Accurate sub-classification of other types of acute 
myeloid leukaemia using PANDA analysis alone was inconsistent. However,  the accuracy in 
classifying leukaemia was improved when the Advia cytogram was used in conjunction with 
morphological analysis, as 90% (135/150) of cases were accurately classified.   
 
The sensitivity and specificity of the peroxidase cytogram in evaluating myeloperoxidase 
(MPO) activity was 85% and 88.6% respectively.  The agreement between cytogram 
peroxidase activity and the reference methods was 89.1% and the Cohen’s kappa was 76.9%. 
To the best of our knowledge, there is no data comparing peroxidase activity on the cytogram 
to other methods.  
 
In conclusion, it was shown that the routine use of the Advia cytograms in conjunction with 
the morphology findings provides invaluable information in the initial screening of leukaemia.  
In cases with indistinct morphology, the cytograms have the potential to aid in a provisional 
classification. The peroxidase activity from the cytogram could be used as a surrogate marker 
for myeloperoxidase activity in leukaemia. Moreover, a tentative diagnosis of an APL is 
possible by simple analysis of the cytogram resulting in earlier diagnosis which  could be life-
saving.  
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Chapter 1: BACKGROUND 
 
1.1  Introduction 
Leukaemia is characterized by the uncontrolled proliferation of haematopoietic cells and 
displacement of normal precursors in the bone marrow.  In South Africa the incidence of 
leukaemia in adults is estimated to be 2.5 per 100 000 (1).  Leukaemia is the most common 
cause of childhood cancers representing approximately 19-31% of all cancers worldwide. (1). 
However in Africa approximately 3.6% of all childhood cancers are due to leukaemia.  Some 
haematological malignancies have a strong association with Human Immunodeficiency Virus 
(HIV) infection and in South Africa approximately 80% of patients diagnosed with Burkitt 
lymphoma/leukaemia and Diffuse large cell B lymphoma/leukaemia are HIV positive (2). 
 
Despite advances in therapeutic technology, mortality associated with leukaemia remains high. 
In Africa, 10,600 females and 11,200 males demised as a result of leukaemia in 2008 (1). The 
significant mortality rate has been attributed in part to delayed diagnosis which is the direct 
result of the lack of screening and diagnostic services in many areas in Africa (3), in particular 
rural healthcare facilities. Early detection and classification of leukaemia allows the clinician 
to promptly initiate the most appropriate treatment plan, as the prompt initiation of 
chemotherapy has been shown to confer a better prognosis(4). 
 
The Full Blood Count (FBC), differential count and review of peripheral blood smear usually 
are the first line investigations that alert the clinician to a possible underlying leukaemia, but 
further investigations are required to confirm the diagnosis and classify the leukaemia before 
appropriate therapy can be commenced.  
 
Acute promyelocytic leukaemia (APL) is a haematological emergency which requires prompt 
initiation of Al-trans retinoic acid (ATRA) to reduce the associated coagulopathy and reduce 
mortality(5, 6). A quick and simple method that can be used to confirm and classify leukaemia 
could therefore be lifesaving. The aim of this study was to determine if the FBC, differential 
count and white blood cell (WBC) cytogram assessment from an automated haematology 
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analyser was as reliable as morphological assessment in the classification of leukaemia when 
compared to flow cytometry.  
 
1.2 Classification of leukaemia 
The World Health Organization (WHO) and French American British (FAB) classifications of 
leukaemia are widely used for leukaemia diagnosis and classification. Accurate classification 
is needed as it influences management decisions and hence the overall prognosis of the 
patients (7).  
 
Leukaemia is classified as acute or chronic depending on the presence and number of blasts in 
the peripheral blood and/or bone marrow. In addition the clinical course of the disease can 
suggest whether the leukaemia is acute/chronic.  Morphologically acute leukaemia is defined 
as the presence of >/= 20% blasts in the peripheral blood or bone marrow, while chronic 
leukaemia is a clonal haematological disorder whereby the blast count represents less than 
20% in the peripheral blood or bone marrow and runs a chronic clinical course (7). 
 
The second step in the classification is to determine whether the leukaemia arises from a 
myeloid or lymphoid lineage, as the treatment regimens are different for myeloid and 
lymphoid leukaemia (8-10). Adults and children diagnosed with acute lymphoblastic 
leukaemia (ALL) require adjunctive steroids in addition to chemotherapy(11).  Morphological 
characteristics such as the presence of Auer rods and specific immunophenotypic surface 
markers in the blasts confirm the myeloid lineage of the leukaemia (7). The FAB 
classification, developed in 1976 (12) further sub classifies acute myeloid (AML) (Table 1.1) 
and lymphoid leukaemias (Table 1.2). Conventionally this is performed by morphological and 
cytochemical  findings. 
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Table 1.1:FAB classification of acute myeloid leukaemia(12) 
Type Name 
M0 Minimally differentiated acute myeloblastic leukaemia 
M1 Acute myeloblastic leukaemia, without maturation 
M2 Acute myeloblastic leukaemia, with abnormal maturation 
M3 Acute promyelocytic leukaemia 
M4 Acute myelomonocytic leukaemia 
M5 Acute monoblastic leukaemia (M5a) or Acute monocytic leukaemia 
(M5b) 
M6 Acute erythroid leukaemia 
M7 Acute megakaryoblastic leukaemia 
 
Table 1.2: FAB classification of acute lymphoblastic leukaemia(12) 
 Type  
ALL-L1 Small uniform cells 
ALL-L2 Large varied cells 
ALL-L3 Large varied cells with vacuolation 
 
In newly diagnosed paediatric Precursor B-cell ALL, the day 8 blast count  after a seven day 
induction pre-phase with corticosteroids influences prognosis and further treatment 
stratification of these patients. Patients with a reduction in the peripheral blood blast count to 
<1x10^9/l have a more favourable prognosis (8). In most academic centres, the day 8 blast 
count is determined by immunophenotypic analysis. 
 
1.3  Diagnosis of leukaemia 
The diagnosis and classification of leukaemia currently requires a combination of approaches 
and these include assessment of the FBC, differential WBC count, bone marrow aspirate and 
trephine biopsy examination, cytochemical stain evaluation, immunophenotyping,  
Fluorescence in situ hybridisation (FISH), as well as molecular and cytogenetic analyses(7). 
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1.3.1  The Full Blood Count (FBC) 
The FBC is an investigation that quantifies leucocytes, red cells and platelet parameters.  FBC 
analytes can be increased or decreased when compared to the reference ranges and this 
suggests underlying disease. In leukaemia the white cell count can be normal, reduced or 
elevated. Causes of cytopenias in the background of leukaemia include displacement of 
normal haemopoiesis by an infiltrate or ineffective haemopoiesis when an acute leukaemia 
transforms from an underlying clonal myeloid disorder. Some lymphoproliferative disorders, 
for example chronic lymphocytic leukaemia,  can be complicated by auto-immune haemolytic 
anaemia and these patients can present with anaemia and features of haemolysis. 
 
The differential count and microscopy identifies quantitative and qualitative abnormalities of 
the leucocyte population. Traditionally microscopic review based on the manual count of one 
hundred white blood cells on a peripheral smear was the gold standard for evaluation of the 
differential count. However concerns have been raised regarding the precision and accuracy of 
this method. Three types of errors have been identified: statistical error as only 100 cells are 
being analysed, distribution error due to the inconsistent distribution of cells on the smear and 
subjective error as the result obtained is dependent on the experience and skill of the 
morphologist (13). Automated haematology analysers employ a number of principles to 
produce accurate and precise results with a significant improvement in turnaround time when 
compared to manual methods (13). The instruments that have been developed thus far utilise 
the following principles: impedance measurement, scattered laser light, high frequency 
measurement and fluorescence measurement via flow cytometry (13). Additionally, automated 
analysis of peripheral blood samples include the use of morphology flags to alert one to the 
need for  manual review of the peripheral smear which may be required when there is an 
immature population of cells (14, 15). 
 
1.3.2  Morphological assessment of bone marrow and peripheral blood smear 
One of the indications for a bone marrow procedure is to confirm and diagnose a leukaemia 
and to assess residual haemapoietic activity, as the WHO favours the use of bone marrow 
material in the diagnosis of leukaemia. Analysis of the marrow involves assessing if the 
cellularity is age appropriate and if normal haemapoiesis is displaced by an underlying 
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malignancy.  However, the diagnosis of leukaemia is sometimes made from the morphological 
assessment of a peripheral smear. 
 
The presence of Auer rods in leukaemic blasts is in keeping with the diagnosis of a myeloid 
leukaemia. Additionally, residual haemapoiesis is assessed for dysplasia as this can be used to 
determine the lineage of the leukaemic population. An example of this is AML with abnormal 
myeloid maturation (FAB M2) whereby the presence of >/= 20% blasts and morphological 
features of dysplasia in the background maturing and mature granulocytes (pelgerised, 
hypogranular neutrophils and disordered cell nucleation) suggest a myeloid origin.  Leucocyte 
cytochemistry staining (myeloperoxidase (MPO), specific esterase and non-specific esterase) 
may also be required to sub classify AML,but this requires the expertise of a trained and 
experienced technologist to prepare the cytochemistry and pathologist to interpret the results 
(7, 16). 
 
1.3.3  Flow cytometry 
Flow cytometry is a technique that uses hydrodynamic focusing to analyse single cells as they 
pass through the light emitted from a laser. Fluorescent monoclonal antibodies are used to 
detect specific membrane, cytoplasmic or nuclear antigens, which are used to detect the 
presence of blasts, immature precursors or mature cells and the lineage of the abnormal 
population.  It allows for the rapid analysis of up to 10000 events.  Flow cytometry is used to 
confirm the diagnosis and to classify the leukaemia (7). 
  
Flow cytometry is expensive, time consuming and requires a skilled technologist to process 
samples. Appropriate knowledge and skills are required to interpret the results.  In many 
academic centres analysis of samples for flow cytometry does not occur after working hours 
which results in a delay in diagnosis. Simpler alternatives to confirm the diagnosis of a 
haematological malignancy are therefore required. 
 
1.3.4  Molecular diagnostics 
Over the years, molecular diagnostic assays have influenced the classification of leukaemias. 
These tests include cytogenetic, FISH, Polymerase Chain Reactions (PCR) and microarray 
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analyses. The aim of these tests is to detect genetic aberrations which help to confirm the 
diagnosis, prognosticate and direct management of leukaemia (7). 
 
1.3.5  Limitations of the current diagnostic strategy 
Owing to a combination of high volumes of morphologic assessments required as a result of 
the HIV epidemic(16), decline in staff numbers due to natural attrition, current high demand 
for experienced technologists/pathologists overseas and poor output of training institutions, 
there is a critical shortage of morphologists in South Africa (14, 17). This together with the 
manual nature of morphologic assessment has a negative impact on the turnaround time for the 
diagnosis of haematological malignancies(18). Furthermore molecular assays are expensive, 
labour intensive, time consuming and again require skilled medical technologists/pathologists.  
  
The grave shortage of morphologists in rural areas further delays diagnosis, as the FBC and 
differential count have to be referred to central laboratories. This delays the transfer of patients 
to oncology units, further work-up and management which has a negative impact on 
prognosis.  Hence there is a need to improve the diagnostic approach so that treatment can be 
accessed earlier. The use of automated haematology analysers in the morphologic evaluation 
of haematological malignancies is a possible solution (14, 19, 20) as the FBC and differential 
count are the initial alarm of an undiagnosed leukaemia. 
 
1.4  The value of automated haematology analysers in classifying leukaemia 
In addition to generating the FBC and differential count, most current haematology analysers 
produce morphology flags to highlight the presence of blasts and other abnormal cells. Many 
studies have evaluated the sensitivity and specificity of automated haematology analysers by 
comparing the differential counts, and detection of abnormal white blood cells in the 
peripheral blood to manual review of the peripheral smear(19, 21, 22). The results of these 
studies are conflicting. The differential counts obtained from the ABX Pentra 120, Abbot 
CELL-DYN Ruby, the Sysmex XT-2000i and Coulter STKS showed good correlation to the 
manual differential count(19, 23). The Advia 2120 haematology analysers used in our 
laboratory also show good correlation with the manual differential count (24).  In contrast, 
review of the Beckman Coulter LH750 reported slightly higher monocyte counts and the 
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Advia 120 reported lower monocyte counts than the reference method (25).  The overall 
sensitivity of automated haematology analysers in detecting blasts is variable (25). 
 
The Coulter VCS system uses volume, conductivity and light scatter to analyse FBC and 
differential counts. The predictive value of this analyser to identify leukaemic samples is 
greater than 90%. However differentiating the subtypes of AML using the FAB classification 
was difficult as the blasts from the cases that were classified as M4/M5 FAB cases clustered in 
the monocyte region of the scatterplot(21). 
 
Performance evaluation of the five part differential patterns of blasts from the DXH 800 
(Beckman Coulter) and XE-2100 (Sysmex) in samples with more than 10% blasts revealed 
that both analysers counted most lymphoblasts as lymphocytes (85% of cases) and 
myeloblasts as monocytes (74.3% of cases). Although the blast flag was raised in 91.2% of the 
cases, the blasts were counted as monocytes or lymphocytes in the differential count. The two 
cases of T-cell acute lymphoblastic leukaemia that did not generate a blast flag 
morphologically had a high nuclear cytoplasmic ratio and coarse chromatin, which probably 
resulted in the blasts being analysed as lymphocytes(21). 
 
A new haematology analyser, Haematoflow (Beckman Coulter, USA), uses principles of flow 
cytometry and a panel of monoclonal antibodies to determine a 16 part WBC differential 
count. There was a good correlation in the blast counts detected by the Haematoflow, however 
the analyser was unable to confirm T-cell lineage in ALL (26).  
 
1.5 The Advia 2120i haematology analyser 
The Siemens Advia 2120 (Siemens Healthcare Diagnostics, Deerfield, Illinois, USA) is 
another example of an automated haematology analyser (24). The Advia 2120 measures the 
total and differential WBC count using principles of flow cytometry and a combination of 
reactions that occur within the Peroxidase and the Basophil/nuclear lobularity channels. 
Cluster analysis of the cells within each channel is used to generate a cytogram and the pattern 
that emerges has been shown to assist with the subtyping of haematological malignancies (27). 
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a. Peroxidase cytogram 
Reagents are used to stain intracellular myeloperoxidase. As the cells pass through a flow cell 
the absorbance of light is used to measure the intensity of myeloperoxidase activity and the 
light scatter measures the size and complexity of cells. This generates a scatter plot with the x-
axis representing increasing intensity of peroxidase staining and the y-axis representing 
increasing cell size. 
 
b. Basophil cytogram 
The Baso reagent lyses the red blood cells, platelets and the cytoplasm of all WBCs except the 
basophils. The WBCs pass through a laser flow cell and the size and complexity of cells are 
detected and recorded on the basophil cytogram. The x-axis records the high angle scatter 
which detects the nuclear complexity and the y-axis reflects cell size. 
 
The patterns that emerge on the Peroxidase and Basophil cytograms of a normal blood sample 
are illustrated in Figures 1.1 and 1.2 respectively. 
Figure 1.1: Peroxidase cytogram (27) 
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Figure 1.2: Basophil cytogram(27) 
 
1.5.1  Peroxidase and nuclear density analysis (PANDA) system 
Over the years an analysis system to detect and classify haematological malignancies 
according to pattern recognition of the cytograms obtained from the Advia analyser has 
emerged (28, 29). This system, referred to as Peroxidase activity and nuclear density analysis 
(PANDA), could potentially allow for faster recognition of leukaemias even before a 
peripheral smear is reviewed by a morphologist. The PANDA system was initiated in 2001 by 
G.Onofrio (29) and further explored by G.J.Gibbs in 2005(28). 
  
This analysis system relies on the PANDA  grid that integrates the patterns that are produced 
from the peroxidase and basophil cytograms (Table1.3). The different patterns are explained 
in section 3.2 of the results. 
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Table1.3:PANDA classification grid (29) 
 P0 P1 P2 P3 P4 P5 P6 
D0 CLL,PLL, 
HCL,ALL(L1), 
Total MPOdef 
Severe 
MPO 
def 
Partial  
MPOdef 
CML CML AIDS 
MDS 
 
D1 ALL(L1-L3), 
NHL,M0, M5a, M6, 
M7 
M1, M5a, 
M2, M4 
M2, M4, M5a, 
M5b, M1 
M2, M4, 
CML-BC 
M2, M3v, 
M4 
M3v,CML 
(at) 
M3 
D2 viral 
disease 
      
CLL, Chronic Lymphocytic Leukaemia; PLL, Prolymphocytic leukaemia; HCL, Hairy cell leukaemia; 
MPO, Myeloperoxidase; def, deficiency; ALL, Acute lymphoblastic leukaemia; NHL, Non Hodgkin 
lymphoma;CML,Chronic Myeloid Leukaemia; BC, blast crisis; V,Variant ; At, atypical; AIDS,  
Acquired immunodeficiency syndrome; MDS, Myelodysplastic syndrome 
 
The advantage of this approach is that less skill is required and an initial screening and 
classification of a haematological malignancy is possible as soon as the FBC sample is 
analysed(28-31). The other advantage is improved laboratory turn around time. The current 
system requires a slide to be produced, stained, and reviewed by a technologist who then refers 
to the pathologist for final assessment and communication with the clinician. The use of the 
PANDA system will eliminate many of these steps. 
  
The Advia cytograms have the potential to classify a leukaemia as acute or chronic (refer to 
section 3.2), MPO positive or negative and to sub classify Acute myeloid leukaemias (AML) 
according to the FAB classification. Some automated analysers have shown variable results in 
detecting blasts as lymphoblasts were counted as lymphocytes and myeloid blasts were 
counted as monocytes(21). Accurate blast detection is essential to differentiate acute and 
chronic leukaemias.  However, the Advia 2120 demonstrated 100% sensitivity in detecting 
blasts and flagged samples that had only 2% blasts present(24). Using the PANDA approach, 
the Advia analyser displayed a 94.4% and 95.2% specificity for AML cases and a specificity 
of 100% for ALL (24, 32). 
 
The results from studies conducted in the developed world cannot be extrapolated to the local 
setting as patients often have concomitant chronic infections such as HIV which may alter the 
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morphology. Our study explores the value of the Advia 2120 in leukaemic subtyping  in a high 
throughput  laboratory.   
 
1.6   Myeloperoxidase activity in leukaemic blasts 
Enzyme cytochemistry on peripheral blood smears or bone marrow aspirate slides is 
traditionally regarded as the gold standard for assessment of MPO activity in leukaemic blasts 
in order to confirm an AML and identify subtypes of AML (16). The development of lineage 
specific monoclonal antibodies, including cytoplasmic MPO, has established the role of 
immunophenotypic analysis in the classification of AML (7). There are varied results on the 
performance of conventional cytochemistry (CC) and immunophenotypic analysis in the 
assessment of MPO activity in leukaemia. Some studies suggest that CC is superior to 
immunophenotypic analysis (33) and others highlight that immunophenotypic analysis is the 
more sensitive technique (34, 35). 
 
The accuracy of the two methods depends largely on the technical ability of staff to prepare 
reagents and samples, the presence of successful positive and negative controls, and a 
diagnostician that can confidently interpret the findings.  In addition monoclonal antibodies 
are expensive. Within the National Health Laboratory Services (NHLS) CC and 
immunophenotypic analysis are usually performed in the academic setting.  
 
The peroxidase cytogram on the Advia printout could potentially provide information on the 
MPO activity in leukaemias prior to a patient sample reaching a central laboratory. To date, a 
literature search reveals no studies that have compared peroxidase activity on the Advia 
printout to immunophenotypic analysis and CC.      
 
1.7  Research Hypothesis 
We hypothesised that in the initial classification of haematological malignancies from 
peripheral blood samples, the FBC, differential count and cytograms generated by the Advia 
2120 are as accurate as manual morphologic assessment. 
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1.8  Aim and Objectives 
The aim of this study was to determine the accuracy of the  FBC, differential count and WBC 
cytogram assessment by the Advia 2120 using the PANDA classification in the initial 
classification of haematological malignancies.  
 
The study had the following objectives: 
1. To evaluate the performance of the Advia 2120 in the classification of haematological 
malignancies. This consisted of:  
a. Comparing the diagnosis obtained by either the Advia PANDA classification 
system and/or morphological assessment to the final diagnosis obtained on flow 
cytometry. 
b. Comparing the myeloperoxidase activity obtained by the Advia Peroxidase 
cytogram to cytochemical and flow cytometry MPO analyses. 
2. To correlate the Day 8 blast count in paediatric acute lymphoblastic leukaemia 
obtained by flow cytometry to that from the Advia 2120. 
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Chapter 2: MATERIALS AND METHODS 
 
2.1  Study design and study population 
The flow cytometry records at the National Health Laboratory Services (NHLS), Charlotte 
Maxeke Johannesburg Academic Hospital (CMJAH) were reviewed from November 2009 to 
May 2012, to identify cases of leukaemia. These included adult (>/= 15 years) and paediatric 
(<15 years) patients who were admitted either to CMJAH or Chris Hani Baragwanath 
Academic hospital (CHBAH).  Leukaemia cases confirmed by flow cytometry that did not 
have an FBC analysed by the Advia haematology analyser at the haematology laboratory at 
CMJAH were excluded. The FBC and differential count of all cases recruited from CHBAH 
were re-analysed on the Advia haematology analyser at CMJAH.  
 
 
Ethical clearance was obtained from the Human Research Ethics Committee of the University 
of the Witwatersrand, Johannesburg prior to data collection. The clearance certificate number 
is M110323 (Appendix 1). 
 
2.2  Sample collection 
The investigations (flow cytometry, full blood count with differential and morphological 
assessments) for each case were requested by the treating physician as part of the diagnostic 
work up. No new samples were obtained from the patients specifically for this study. 
 
Peripheral blood sample collected in an Etheylenediamine tetra acetic acid (EDTA) 
anticoagulated tube and the routine FBC and differential count were analysed on the ADVIA 
2120 (Siemens healthcare diagnostics, Illinois, USA). A printout of the result, including the 
WBC cytograms, for each case was collected. Cases prior to April 2011 were retrieved from 
the laboratory data storage system , as the laboratory backs up data to prevent data overload, 
while the remaining cases were retrieved directly from the instrument database. 
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Samples for flow cytometry were collected in lithium heparin tubes and submitted for 
analysis. The complete immunophenotypic analysis report was authorised on the laboratory 
information system, WxDisa. The report included the final diagnosis, as well as the MPO 
result and Day 8 blast count if applicable. 
 
The peripheral smears of the retrospective leukaemia cases, which were filed  with the bone 
marrow aspirate samples in the laboratory in alphabetical order,  were collected.  A peripheral 
smear was made from the FBC samples received from CHBH that were reanalysed on the 
Advia 2120.  
  
 
2.3  Laboratory procedures for sample analysis 
Laboratory specific standard operating procedures were followed for the analysis of the flow 
cytometry,  FBC,  cytochemistry samples and the manual review of peripheral smears (36-42).  
 
2.3.1  Immunophenotypic analysis 
Peripheral blood mononuclear cells were separated by density gradient centrifugation using 
the Ficoll Separation Technique (Ficoll/Histopaque), washed with phosphate buffer solution 
and incubated with monoclonal antibodies conjugated with fluorescein isothyocynanate 
(FITC), phycoerthrin (PE), peridinin chlorophyll protein complex (PerCP) and 
allophycocyanin (APC) (36). The monoclonal antibodies are specific for cellular antigens 
known as cluster of differentiation (CD). Morphological assessment and standardised 
diagnostic panels were used to guide the choice of monoclonal antibodies (37). According to 
the laboratory standard operating procedure, if an acute leukaemia is suspected 
morphologically, an acute screen comprising of blast surface and lineage specific markers 
(myeloid, B and T-cell markers) are chosen (Table 2.1). If the morphological features are in 
keeping with a chronic lymphoproliferative disorder a chronic screen (B, T-cell surface 
markers and disease specific markers) is used (Table 2.1). 
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Table 2.1 Immunophenotypic markers used in flow cytometry 
 Blast surface 
markers 
Myeloid 
antigens 
Lymphoid 
Antigens 
Other antigens 
Acute leukaemia CD34, CD117 CD13, CD33, 
CD11b, CD13, 
CD14,  CD15, 
cytoplasmic 
myeloperoxidase 
B-cells 
CD19, CD20, 
CD22,  kappa, 
lambda 
 
Tcells 
CD3, CD4, 
CD8, CD2, 
CD7, CD5, 
CD1a 
cytoplasmic 
CD3 
CD45 
HLA-DR 
Glycophorin A 
CD10 
CD5, CD10 
 
 
 
 
 
 
 
CD11c, CD103 
 
 
 
 
CD25 
CD16, CD56 
Chronic 
leukaemia 
  B-cell 
CD19, CD20, 
CD23, kappa 
lambda 
 
T-cells 
CD3, CD4, 
CD8, CD7, CD2 
Myeloma panel CD38, CD56, CD45, CD19, CD138, CD20, kappa, lambda 
CD, clusters of differentiation 
 
Analysis was performed on a dual-laser FACS Calibur (Becton Dickinson,San Jose, CA,USA) 
equipped with Cell Quest Pro and PAINT-A-GATE Pro Software, after gating on 10 000 
events per sample. All samples were analysed in the presence of appropriate isotypic controls. 
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2.3.2  Morphological analysis of cases 
A Nikon ECLIPSE E400 microscope (Nikon, Tokyo, Japan) was used to analyse the 
peripheral smears. The slides were stained with the May-Grünwald-Giemsa stain and a 
manual count was performed on 100 WBCs at the 50x magnification (38). If ≥ 
20% blasts were seen, a diagnosis of acute leukaemia was made. The absence 
of blasts or a blast count of <20% were indicative of chronic leukaemia. The presence of Auer 
rods in the blasts favoured a leukaemia of myeloid lineage. The morphology was then 
reviewed in conjunction with the cytograms and a provisional diagnosis made.  
 
The initial morphological assessment was made by an independent medically qualified  
morphologist (registrar or pathologist), a provisional diagnosis was made and this was used to  
to guide immunophenotypic analysis. The morphological assessment for each case was 
repeated by the investigator to ensure that she remained blinded to the final diagnosis. At 
study completion, the morphology findings obtained by the investigator were compared to the 
previous findings noted by the initial morphologist. 
 
2.3.3  Advia WBC cytogram analysis 
The Advia 2120 has two independent channels which are used to generate a WBC and 
differential count using peroxidase and Baso reagents. The Basophil method generates the 
total WBC and the peroxidase method provides the differential count and a secondary WBC. 
Commercial controls were analysed twice daily on the Advia 2120 and patient samples are 
only processed if controls are within two standard deviations of the known target value (39). 
 
Myeloperoxidase activity was assessed from the peroxidase chamber using the patterns 
described by G. Onofrio(32). Cells that scattered near the y-axis have no myeloperoxidase 
while cells that scattered further away from the y-axis have increasing myeloperoxidase 
activity. The results of the Advia peroxidase cytogram were compared to the myeloperoxidase 
result obtained by flow cytometry and/or cytochemical staining. The basophil cytogram was 
used to assess the pattern of the mononuclear cell cluster (Refer to section 3.2).  
 
The Advia triggers a blast flag when the % blasts is between 1.5% to 5.0% and %LUC   
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 ≥ 4.5%; or % blasts > 5.0% of the total WBC, or % BASO + %BASO Suspect + %   
 BASO Saturation ≥ 10% (39).  
 
a. Pilot study to define the criteria to be used in the analysis of the Advia 2120 
White blood cell cytograms 
Ten randomly selected cases were analysed to identify emerging patterns that would 
assist in the classification of cases and to develop a standardised and objective method 
of reviewing cases in this study. The analysis of the cytograms of each case was based 
on information obtained from the Advia 2120 user manual and PANDA analysis 
guidelines. We also looked for additional parameters from the Advia printout that 
assisted in classification of leukaemia. These included: patient age, WBC, 
haemoglobin, platelet count and blast flag. 
  
The following approach was used to analyse each cytogram: 
If the blast flag was triggered by the analyser, an acute leukaemia was suspected. The 
patterns seen on the basophil cytogram were used to classify the sample as D0 (Figure 
3.2), D1(Figure 3.3) or D2 (Figure 3.4), and the peroxidase cytogram pattern was used 
to classify the sample as P0-P6 (Figure 3.1) (27).The baso and peroxidase pattern 
classification of each case were integrated and the PANDA classification grid (Table 
1.3) was used to determine the differential diagnosis. The age of the patient and the 
severity of cytopenias were used to determine the most likely diagnosis. 
 
2.3.4  Myeloperoxidase activity 
Intracellular MPO was performed by cytochemical staining or by flow cytometry. 
Conventional cytochemical staining was performed by fixing the slide for sixty seconds, 
washing with tap water and air drying. The slide was then dissolved in 3-amino-9 
ethylcarbazole, dimethylsulfoxide and acetic acid sodium hydroxide. The slides were 
incubated, washed again, counterstained with Mayer’s/Gill haematoxylin, rinsed and air dried.  
The reaction product is brown granular cytoplasmic staining. The presence of staining in at 
least 3% of the blasts is in keeping with an Acute Myeloid Leukaemia (40). 
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Detection of MPO activity by flow cytometry involved the use of Intrastain to fix and 
permaeabilise the peripheral blood mononuclear cells followed by the addition of the 
myeloperoxidase monoclonal antibody. The sample was incubated and then analysed by the 
flow cytometer. A second tube that was negative for MPO antibody was used as a control (41). 
On flow cytometry positive MPO staining in >/= 10% blasts is in keeping with a myeloid 
leukaemia. Assessment of MPO activity from the Advia printout is outlined in section 2.3.3. 
 
2.3.5  Day 8 blast count 
A whole blood sample is used for the analysis of the Day 8 blast count. The sample was first 
analysed on the Advia 2120 to obtain the total WBC. Then, 100ul of whole blood was added 
to a tube with monoclonal antibodies, incubated for 15 minutes at room temperature, lysed 
with ammonium chloride and washed with phosphate buffer solution. The choice of 
monoclonal antibodies was dependent on the presentation immunophenotype. The sample was 
analysed on the FACSCalibur (42). The Day 8 blast count was correlated with morphological 
assessment and was reported as an absolute value of the total White cell count.  
 
The results of %LUC and % blast suspect(reflecting the percentage of abnormal cells in the 
D8 sample) generated by the Advia were  used to calculate an estimated day 8 blast count. The 
absolute Day 8 blast count was calculated using the following calculation:  
 
[(%𝐿𝑈𝐶 + % 𝑏𝑙𝑎𝑠𝑡 𝑠𝑢𝑠𝑝𝑒𝑐𝑡)/100] 𝑥 𝑊𝐶𝐶(𝑥10^9/𝑙)  =  𝐷8 𝑏𝑙𝑎𝑠𝑡 𝑐𝑜𝑢𝑛𝑡 (𝑥10^9/𝑙) 
 
The result of the above calculation was recorded as <1x10^9/l or >1.0x10^9/l, and was 
compared to the value obtained on flow cytometry. 
 
2.4  Data analysis 
All of the results were tabulated on Microsoft excel spreadsheets.  The final diagnosis obtained 
from analysis of the WBC cytograms, morphology and the combination of both analyses were 
compared to flow cytometry.  
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For the purpose of this study, the following definitions were used: 
Diagnosis: the final classification of leukaemia 
Inaccuracy: discrepant result obtained on cytogram/morphology or combination when 
compared to the final diagnosis obtained by flow cytometry 
True positive (TP): diagnosis made on cytogram/morphology or combination  correlated with 
the final diagnosis obtained by flow cytometry 
 False negative (FN): a diagnosis was not made on the cytogram/morphology or combination 
and a diagnosis was made by flow cytometry 
False positive (FP): the diagnosis made on the cytogram/morphology  or combination did not 
correlate with the diagnosis made by flow cytometry.  
 
The results of each analysis were classified as TP, FN, FP when compared to the final 
diagnosis obtained by flow cytometry. True negatives could not be calculated as only cases of 
leukaemia were included. Refer to Appendix B which includes the raw data of the FN and FP 
cases that were classified using PANDA analysis.  
 
True negatives were only calculated for specific classes of leukaemia and this enabled the 
calculation of sensitivity and specificity for these classes. The positive predictive value (PPV) 
and accuracy were calculated for each category using the following formulas: 
𝑃𝑃𝑉 =
𝑡𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠
𝑡𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠 + 𝑓𝑎𝑙𝑠𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠
𝑥100% 
 
Accuracy=
𝑡𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠+𝑡𝑟𝑢𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠
   𝑡𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠+𝑓𝑎𝑙𝑠𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠+𝑓𝑎𝑙𝑠𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠+𝑡𝑟𝑢𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠
𝑥100% 
 
Similarly the myeloperoxidase activity assessed on the peroxidase cytogram was compared to 
flow cytometry and/or cytochemistry. A true positive (TP) was defined as positive peroxidase 
activity on all methods. A true negative (TN) was defined as absence of peroxidase activity on 
all methods. A false positive (FP) was defined as positive peroxidase activity on cytogram 
analysis and negative MPO on the reference methods and a false negative (FN) was defined as 
negative MPO on peroxidase cytogram and positive MPO on the reference method. The 
Cohen’s kappa, Mcnemar test for symmetry, sensitivity and specificity were calculated using 
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the evaluation protocol (EP) evaluator (Data innovations, Vermont, USA). The EP evaluator is 
a software programme designed to evaluate and measure clinical laboratory performance of 
testing methods.  
 
Microsoft excel 2010 was used to determine the correlation between the D8 blast counts 
obtained from the Advia printout and the reference method. 
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Chapter 3:RESULTS 
 
3.1  Study population 
206 cases of immunophenotypically confirmed leukaemias were identified from review of the 
flow cytometry records. The Advia printouts of 56 cases could not be retrieved due to 
technical issues with data storage. This study was therefore conducted on 150 cases, of which 
50 cases were paediatric (<15 years old) and 100 cases were adults (>/= 15 years old). The 
patients’ ages ranged from nine months to 82 years and the overall male: female ratio was 
1.3:1. 
 
The spectrum of haematological malignancies (Table 3.1) included ALL (49/150; 32.1%), 
AML (48/150; 32.1%), CML (15/150; 10.1%), CLL (20/150; 13%), other chronic 
lymphoproliferative disorders (3/150; 2%), Non-Hodgkin lymphoma (NHL) (9/150; 6%) and 
<1% plasma cell leukaemia. There were two cases of Acute Leukaemia of ambiguous lineage. 
Classification of leukaemia was not possible in one case due to insufficient sample volume for 
immunophenotypic analysis and the patient demised before further investigations. 
 
Table 3.1: Spectrum of haematological malignancies in patient cohort 
Haematological malignancy Number of patients (n=150) 
Acute lymphoblastic leukaemia 49 
Acute myeloid leukaemia 48 
Chronic myeloid leukaemia 15 
Chronic lymphocytic leukaemia 20 
Non- Hodgkin lymphoma 9(8/9 Burkitt lymphoma) 
Plasma cell leukaemia 1 
Other Chronic Lymphoproliferative disorders (mantle cell 
lymphoma, follicular lymphoma) 
5 
Acute leukaemia (ambiguous lineage) 2 
Acute leukaemia (no lineage) 1 (insufficient sample, patient 
demised) 
 
The provisional morphology diagnoses obtained by the investigator and the initial 
morphologist assessment were the same in all the cases (150/150; 100%).  
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3.2  Analysis of the white blood cell cytograms 
The pilot study included the following spectrum of leukaemia cases: ALL (4/10), AML (2/10), 
CLL(1/10), APL (2/10) and NHL (1/10). The lymphoid cases showed a true downward left 
lateral shift of the mononuclear cell cluster pattern on the basophil cytogram and the myeloid 
cases showed a right shift towards the polymorphonuclear cell gate (Figure 1.2). 
The peroxidase cytograms were classified as P0-P6 (Figure 3.1 and Table 3.2) and baso 
cytograms as D0-D2 (Figures 3.2, 3.3 and 3.4).  
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Approximate areas corresponding to leukaemia cell differentiation according to 
degree of peroxidase activity (27) 
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Table 3.2: Description of peroxidase patterns on cytogram P0-P6 (27) 
Category Pattern Description 
P0 Peroxidase negative with no myeloid 
differentiation 
P1 Scattering at the top of the main cell cluster 
indicating the presence of some cells with 
MPO activity and either early or partial myeloid 
differentiation 
P2 Homogenous cluster of cells separated from 
the LUC area continuing across the monocyte 
area and about to enter the neutrophil area of 
the cytogram 
P3 Moderate to strong peroxidase activity and 
homogenous cell size 
P4 Strong heterogenous myeloperoxidase activity 
P5 Strong peroxidase activity in very large cells 
P6 Extremely intense peroxidase activity 
 
In the D0 pattern the shape of the mononuclear cell cluster is noted as normal (Figure 3.2). 
There is a down/leftward shift of the mononuclear cluster indicating the presence of cells with 
immature chromatin and the blast flag is positive in the D1 pattern (Figure 3.3). In the D2 
pattern there is an upward shift of the mononuclear cluster suggesting the presence of large 
cells with heterogeneous chromatin and is usually blast flag negative (Figure 3.4). 
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Figure 3.2: Basophil cytogram illustrating D0 (27) 
 
 
 
 
 
Figure 3.3:Basophil cytogram illustrating D1(27) 
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Figure 3.4: Basophil cytogram illustrating D2 (27) 
 
 
Analysis of the peroxidase cytogram revealed that the lymphoid malignancies, including ALL, 
CLL and NHL, produced a P0 pattern. However, Acute Myeloid Leukaemia FAB M0 could 
not be excluded from this group as the blasts are negative for peroxidase activity. A P6 pattern 
was observed in APL and combined P2/P3 patterns were observed in other AML cases. Cases 
with a P0 pattern were defined as MPO negative and cases that had a P1-P6 pattern were MPO 
positive.  
 
After identification of the D and P patterns from the basophil and peroxidase cytograms 
respectively, the leukaemia could be classified using The PANDA classification grid (Table 
1.3), which aided in establishing a differential diagnosis for most cases.  The two cases of 
AML, for example, produced a D1 pattern which identified them as an Acute Leukaemia, and 
peroxidase activity was easily demonstrated with P3/P4 patterns in keeping with myeloid 
origin.  Conversely, CLL, which is a chronic lymphoid malignancy produced a D0P0 pattern. 
APL is the only leukaemia with a unique pattern, which is classified according to the PANDA 
system as D1P6. The results of the pilot study suggested that the  P and D patterns that were 
described by d'Onofrio and colleagues may be applicable in our setting.  
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3.3 The PANDA analysis system and morphology in the overall 
classification of leukaemia 
The final diagnosis obtained by analysis of the PANDA system,  peripheral smear morphology 
and combination of the two was  compared to the diagnosis obtained by immunophenotypic 
analysis. Using the PANDA analysis system, 48% (72/150) of cases were accurately 
classified. The inaccuracy was 9.3% (14/150) and 42.7% of cases could not be classified. The 
positive predictive value (PPV) was 88%. The raw data of cases which had discrepant results 
on PANDA analysis are included in Appendix B.   One of the main reasons for the inaccuracy 
was the difficulty in differentiating between acute lymphoblastic and acute myeloid leukaemia 
with the sub type FAB-M0, both of which produce a D1P0 pattern. There were 30 cases with a 
D1P0 pattern. Only 53.3% (16/30) cases that displayed a true downward left lateral shift of the 
mononuclear cell cluster on the basophil cytogram were correctly diagnosed as ALL. An 
incorrect diagnosis was made in 26.7% (8/30) cases based on this pattern. A lateral shift of the 
mononuclear cell cluster towards the polymorphonuclear gate was observed in 6.7% (2/30) 
and these cases were in keeping with a diagnosis of AML. In 13.3% (4/30) cases it was 
difficult to describe the pattern of the mononuclear gate. 
 
Comparison of morphological assessment alone to immunophenotypic analysis accurately 
classified 54% (82/150) of the leukaemia cases with only one inaccurate diagnosis. A final 
diagnosis could not be made in 44% (67/150). The positive predictive value of morphology 
was 99% (Table3.3). However, the accuracy was improved when the ADVIA cytogram was 
used in conjunction with morphological analysis, as 90% (135/150) of cases were accurately 
classified.  5.3% (8/150) were classified incorrectly and a diagnosis was not possible in 7/150 
(4.7%). The positive predictive value using morphology and the ADVIA printout was 94%  
(Table 3.3). 
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Table 3.3: Summary of final diagnosis obtained from PANDA analysis, morphology and  
PANDA analysis plus morphology 
Investigations used for the analysis 
of cases 
TP 
N=150 
FP 
N=150 
FN 
N=150 
Accuracy 
% 
PPV 
% 
PANDA ANALYSIS (CYTOGRAM) 72 14 64 48 88 
MORPHOLOGY 82 1 67 54 99 
PANDA ANALYSIS+ MORPHOLOGY 135 8 7 90 94 
 
True positive (TP): PANDA system or morphology or PANDA system plus morphology correlates with the final 
diagnosis 
False positive (FP): PANDA system or morphology or PANDA system plus morphology does not correlate with 
the final diagnosis 
False negative (FN): No diagnosis obtained from PANDA system or morphology or PANDA system plus 
morphology 
Positive predictive value (PPV) 
 
 
3.4 PANDA system and morphology in the classification of specific 
 sub types of leukaemia 
As PANDA plus morphology produced the highest accuracy, the sensitivity and specificity for 
ALL, chronic myeloid leukaemia and chronic lymphocytic leukaemia were calculated for this 
group. The absence of that specific class of leukaemia was used to define the true negative 
group. The sub-classification of AML using PANDA and morphology was reviewed. 
 
a.  Acute lymphoblastic leukaemia 
The sensitivity of using PANDA analysis in conjunction with the morphology to 
diagnose ALL was 89.6% and the specificity was 99%. 
 
b.   Acute myeloid leukaemia 
The sub-classification of the AML cases is illustrated in (Table 3.4). Of the 48 AML 
cases,  flow cytometry was unable to provide a provisional FAB classification in 19 of 
the cases.  73.7% (14/19) were correctly diagnosed on analysis of the cytogram in 
combination with morphology as AML. 3/19 (15.8%) were incorrectly classified. 
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All 8 cases diagnosed as FAB M3, APL, were accurately classified on cytogram 
analysis based on the distinct D1P6 pattern on the cytograms.  All cases with FAB M2 
and AML transformed from underlying CML were correctly classified and 85% (6/7) 
of the M5b cases (Table3.4). 
 
Table 3.4: Classification of the acute myeloid leukaemia cases 
Type of myeloid leukaemia Number of 
Patients 
Number classified correctly on 
cytogram and morphology 
M1 2 0 
M2 3 3 
M3 8 8 
M4 1 0 
M5a 4 2 
M5b 7 6 
M7 1 0 
AML not classified as FAB 19 14 
AML from CML 2 2 
Total number 48 35 
 
c.  Chronic myeloid leukaemia 
The sensitivity of the PANDA system in diagnosing CML was 100% and the 
specificity was 97.8%. 
 
d.  Chronic lymphocytic leukaemia 
The sensitivity and specificity of the PANDA system and morphology to diagnose 
CLL the sensitivity was 100% and specificity was 100%. 
 
3.5 Comparison of the Myeloperoxidase (MPO) activity obtained from 
 the ADVIA peroxidase cytogram to flow cytometry/cytochemistry 
36.7 % (55/150) had an MPO done on flow and/or cytochemistry. When these results were 
compared to the peroxidase cytogram result, 30.9 % (17/55) yielded a true positive result, 7.3 
% (4/55) yielded a false positive result, 5.4% (3/55) yielded a false negative result and 56.4% 
(31/55) yielded a true negative result. The sensitivity and specificity of the peroxidase 
cytogram in evaluating the presence or absence of MPO are 85% and 88.6% respectively. The 
negative predictive value (NPV) was 91.2% and the positive predictive value was 85.7%  The 
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agreement between cytogram peroxidase activity and the reference methods was 89.1%, the 
McNemar test for symmetry passed with a p value > 0.999 and the Cohen’s kappa was 76.9%. 
 
3.6  Comparison of the Day 8 blast count obtained on the Advia to 
 flow cytometry 
The Day 8 blast count was evaluated in 25 newly diagnosed ALL cases and revealed an r 
value of 0.377 (p<0.05), slope = 0.055 (p<0.05) and y intercept value of 0.354 (p<0.05). In 
88% (22/25) of these cases the day 8 blast count calculated from the Advia printout correlated  
with the value obtained from flow cytometry (i.e.<1x10^9/l or >/=1x10^9/l). In the remaining 
3 cases flow cytometry detected a blast population of >1.0 x10^9/l while the ADVIA detected 
<1.0x10^9/l of % blast suspect and LUC.  
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Chapter 4: DISCUSSION 
 
4.1 The efficacy of the Advia WBC cytograms in the classification of 
leukaemia when using the PANDA classification system 
In an era where the use of automated haematology analysers is growing at a rapid pace, a 
review article by a South African scientist explored the value of the PANDA system in the 
classification of leukaemia, in particular APL (43). To the best of our knowledge there are no 
previous studies from South Africa assessing the PANDA system. In South Africa there is a 
delay in diagnosing and classifying leukaemia owing to the critical shortage of experienced 
morphologists in the peripheral laboratories. Peripheral blood smears are often requested by 
clinicians because cytopenias are common in a population burdened by HIV, Tuberculosis and 
malaria (44, 45). Innovative strategies to improve diagnostic services in laboratories outside of 
the academic centres are necessary to improve patient care (46, 47). Therefore assessment of 
the PANDA system in all leukaemic subtypes was important in our setting. 
 
In our study males were more affected with leukaemia than females, and this finding concurs 
with the reported increased incidence of leukaemia in males (7). The majority of the samples 
were from the adult population and possible reasons for this finding include  transformation to 
an acute leukaemia from underlying chronic leukaemia, concomittant HIV infection, increased 
chronic leukaemias in adults and  increasing genetic mutations with increasing age. 
 
The accuracy of the Advia cytograms to classify leukaemia was only 48% and the accuracy of 
morphology was 54%. The PPV of all cases using the PANDA system was 88% and this 
shows that the ability to classify a leukaemia is high when a pattern can be identified. In our 
study, the accuracy of PANDA was much lower than that obtained by Gibbs (77.8%) and G. 
Onofrio (91.1%) in previous studies. Gibbs correctly classified 100% of the ALL and CLL 
cases on cytogram pattern recognition which improved his overall accuracy. The exact reason 
for the difference in the overall prediction accuracy of the cytograms between this study  and 
Gibbs is uncertain , but it is noted that Gibbs only evaluated four cases of ALL compared to 
the 49 cases analysed in this study  (28, 29). In the pilot study a true downward left lateral shift 
of the mononuclear cell cluster was observed on the baso cytogram in the ALL cases and there 
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appeared to be a right shift of the mononuclear cells towards the polymorphonuclear gate in 
the AML cases. The hypothesis was that a shift toward the mononuclear cell gate may be an 
indication of a myeloid differentiation. However when this pattern was further evaluated, only 
a little more than 50% of the cases were correctly classified. The conclusion is that shifts of 
the mononuclear cell gate is non-specific and cannot be used as a lineage indicator.  
 
In myeloid leukaemia, the presence of a D1 pattern and distinct peroxidase activity were used 
to identify the AML cases.   The CML cases showed a specific pattern which included a D0 
pattern (absence of blasts) and a spectrum of peroxidase activity suggesting varying stages of 
granulocytic maturation. In 40 % of AML cases it was not possible to classify these cases 
according to the FAB classification on cytogram analysis alone.  In all the cases of APL, a 
correct diagnosis was made on evaluation of the cytogram alone due to the distinct D1P6 
pattern. The advantage is that there is no other differential diagnosis for this pattern on the 
classification grid and this was confirmed in a previous study (48). The importance of this 
finding is the impact it has on the immediate management of the patient in terms of reducing 
the bleeding risk and the initiation of Al trans retinoic acid.  However none of the cases 
included in this study were of variant APL, and the pattern of the typical APL may be different 
from the variant. In Gibbs’s retrospective review of AML, four cases of variant APL had 
variable PANDA patterns which included one case with a  P5D1 profile, another case with a 
P4D1 and the remaining two cases with D1P6 pattern (48).  
 
Other than APL, all the other AML subtypes are duplicated across the PANDA classification 
grid (Table 1.3), which makes the classification difficult.  This reflects the heterogenous 
nature of the disease, a finding that was noted previously by Gibbs (28). Interesting 
observations were noted in the  AML M5a and M5b cases: although most of the cases had a 
D1 pattern with varying amounts of peroxidase activity, two of the AML cases with 
monocytoid differentiation had atypical patterns:  D0P0 and D2P3. The reason for this is 
uncertain.  It is possible that because of the spectrum of disease, in some cases the blasts are 
more mature and the ADVIA analyser identifies these cells as more mature cells, hence the D0 
pattern.  The reason for a D2 pattern is not clear, but could be related to the leucocytosis.  
Most AML M5a cases produced the typical D1P0 pattern, except for one which had a D2P3 
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pattern.  Again, this may be due to the leucocytosis or the atypical morphology of the 
monoblasts. As the remaining AML subtypes were not well represented it was not possible to 
determine any further emerging patterns.  The data reaffirmed previous findings that  the 
PANDA classification is a good indicator of AML, but poor at sub-classification except for the 
M3 subtype (28).  
 
In lymphoid leukaemia, the majority of cases (64%) could not be classified after Advia WBC 
cytogram analysis. On review of the PANDA analysis grid, it was noted that the differential 
diagnosis for a D1P0 and D0P0 patterns is very heterogenous.  It is very difficult to commit to 
a single diagnosis based solely on cytogram analysis. The D0P0 pattern includes ALL, CLL, 
PLL and HCL and unless patient demographics and severity of cytopenias are also taken into 
account, it is near impossible to narrow the differential diagnosis. In the paediatric cases that 
presented with a marked leucocytosis and a DOP0 pattern a diagnosis of ALL was favoured as 
CLL, HCL and PLL is unlikely in a child.  In addition the absence of peroxidase activity does 
not exclude the possibility of an AML as M0, M5a, M6 and M7 which are classically MPO 
negative. The remaining cases that could not be classified included the following patterns: 
D2P1, D2P3 and D2P1. The limitation of the PANDA classification grid is that there is no 
differential diagnosis for D2P1 and D2P3 cases. The D2 pattern was associated with a marked 
leucocytosis, suggesting that the distribution of cells on the basophil cytogram is influenced by 
a high WCC. Some of the ALL cases had a D2 pattern which excluded the presence of blasts. 
This could be attributed to varying blast morphology with small cells that had heterogenous 
chromatin and the Advia identifying these cells as lymphocytes.  
 
4.2 Role of the Advia WBC cytograms in combination with morphology in 
the classification of leukaemia 
Morphological analysis accurately identified 54% of cases.  The cases that were diagnosed on 
morphology alone included those with features in keeping with chronic myeloproliferative and  
lymphoproliferative disorders overall favouring CML and CLL respectively, APL, typical L3 
morphology favouring a Non-Hodgkin’s lymphoma,  Auer rods present confirming the 
presence of myeloblasts in AML and  a case with plasma cell leukaemia.  Manual review of 
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peripheral smear remains valuable as subtle morphological features can be missed on 
automated haematology analysers (19). 
 
The diagnosis could not be made on morphology alone mainly in cases of acute leukaemia 
whereby the morphology of the blasts was non-specific making differentiation between 
myeloid and lymphoid blasts very difficult. These included cases of AML FAB  M1, M5a, 
M5b, M7 and 2 cases of acute leukaemia of ambiguous lineage in which the morphology was 
not distinctive to confirm the diagnosis. 
 
However when the Advia printout was used in combination with the morphology findings, 
there was a significant improvement in being able to make a provisional diagnosis with 90% 
of cases being correctly diagnosed. This supports that information obtained from the 
cytograms aids morphology and vice versa. In all except 2 cases with a D0P0 pattern, with 
morphological features of acute leukaemia the correct diagnosis of ALL was made using the 
PANDA classification grid. The 2 cases that were incorrectly diagnosed had a final diagnosis 
of AML, a differential diagnosis that does not feature on the PANDA D0P0 grid. Again this 
supports the heterogeneity of AML, and morphologically these blasts were small and had no 
appreciable features to suggest myeloid origin. Review of flow cytometry and cytochemistry 
results for these two cases suggest that these cases could be classified as AML- FAB M0.  
 
The PPV for morphology and Advia cytogram analysis decreased from morphologic analysis 
alone due to the increased number of false positives (FP=8). Four of the false positive cases 
were AML cases, where the morphology was non-specific and on PANDA analysis a D1P0 
pattern was noted  with a downward lateral shift of the mononuclear cell gate resulting in these 
cases being classified as ALL.  Cases of Acute leukaemia of ambiguous lineage accounted for 
two of the false positive cases. The remaining cases were an ALL case with a D2P1 pattern 
and an AML case with a D2P3 pattern, which do not form part of the  differential diagnosis for 
these categories  on the PANDA classification grid. The case with a D2P1 pattern had 
morphology that was in keeping with an acute leukaemia and because of the apparent presence 
of peroxidase activity a diagnosis of AML was made. This did not correlate with the final 
diagnosis of ALL. A possible reason for this discrepancy could be that the background 
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immature granulocytes were displaying peroxidase activity and on cytogram review these 
populations could not be separated from the large unstained cells, so it appeared that the 
tumour population had a small amount of peroxidase activity. 
 
The remainder of cases that had a D0P0 pattern had morphological features of a chronic 
lymphoproliferative disorders favouring CLL. On review of the PANDA grid, the other 
differential diagnosis included PLL and HCL which usually have distinct morphological 
features. Hence a diagnosis of CLL was favoured and this was confirmed on 
immunophenotypic analysis. 
 
The results show that the combined used of the cytograms with morphology definitely aid in 
the diagnosis of certain leukaemias, in particular cases that have a D0P0 and D1P0 patterns.  
 
4.3 The Advia myeloperoxidase activity 
The sensitivity and specificity of the peroxidase cytogram in predicting the MPO activity was 
85% and 88.6% respectively. The sensitivity was reduced because of the presence of false 
negative results which included the cases of acute leukaemia of ambiguous lineage which had 
a very small population of ~3-5% blasts that were MPO positive on flow cytometry and a case 
of AML with very dim MPO positivity. This indicates that although the Advia MPO correlates 
well with conventional methods, it is limited when the target population with peroxidase 
activity is small.  Four cases yielded a false positive result: The case of Non-hodgkin 
lymphoma had a background leucoerythroblastic reaction and the immature granulocytes that 
showed myeloperoxidase activity could not be isolated from the LUC and a diagnosis of AML 
was made.  Additionally, two cases with a P1 and P2 pattern on the peroxidise cytogram 
analysis were MPO negative on flow cytometry and this could again reflect contamination 
from the background granulocyte precursors where as flow cytometry specifically focuses on 
the blast population. 
 
The above findings highlight the potential use of the peroxidase cytogram to screen for  MPO 
activity.  Conventional MPO cytochemistry is time consuming, requires a skilled technologist 
and expensive control materials. In addition flow cytometry is expensive, time consuming and 
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again needs an experienced technologist.  The EP evaluator (Data innovations) used by the 
NHLS compared the Advia MPO to the reference investigations for MPO:  the McNemar test 
for symmetry passed with a p>0.999 and the Cohen’s Kappa was 76.9%  suggesting that there 
is high agreement between the methods, above what is expected by chance.  To save time and 
reduce laboratory costs assessment of MPO activity from the perox cytogram can be used as a 
screening tool if the blast population is greater than 5%.  
 
The disadvantage of the Advia is its inability to quantify the number of blasts that are MPO 
positive which is important in classifying myelomonocytic leukaemia and acute leukaemias of 
ambiguous lineage. 
 
4.4 Day 8 blast count 
Analysis of the Day 8 blast count revealed that there is poor correlation between the absolute  
values of the blast counts obtained on flow cytometry and the Advia analyser with an R value 
of 0.33.  However when using the clinical significant value of <1.0 x10^9/l (9, 11), 22/25 
(88%) day 8 blast counts calculated from the Advia printout paralleled the value obtained on 
flow cytometry (i.e.<1x10^9/l or >/=1x10^9/l). The Advia under-estimated the Day 8 blast 
count in 3 cases , that  flow cytometry detected >1x10^9/l blasts.  A possible reason for this 
difference included the presence of small lymphoid blasts that were counted by the FBC 
analyser as lymphocytes rather than blasts.   
 
The findings suggest that the Day 8 blast count from ADVIA printout could be used as 
surrogate for flow cytometry as a predictor of prognosis in childhood leukaemia in resource 
constrained areas that do not have access to flow cytometry.  However accurate absolute 
quantification of blasts was affected as in many of the cases the lymphoid blasts were counted 
as lymphocytes by the FBC analyser thereby underestimating the count.  In view of this, it is 
unreliable to use the Day 8 blast count from the ADVIA machine and flow cytometry remains 
the investigation of choice. 
 
4.5 Study limitations 
The following limitations apply to this study: 
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• Although the patient cohort was relatively small, the cases reflect the spectrum of 
leukaemia seen at a tertiary hospital in Johannesburg and are similar to previous studies 
that explored a similar concept (31, 32,  48) .  In the smaller subgroups, in particular the 
AML group  there were too few cases from  the different FAB subgroups and this made 
statistically significant findings difficult. 
• The cytograms and morphology were analysed by one person and this introduced a 
potential bias to the study. To reduce the degree of bias, patient identifiers on the Advia 
printout were erased and assigned a study number.  The cytograms were analysed 
separately and independent of morphology and the final diagnosis. The morphology was 
reviewed at a different time, in isolation of the Advia printout and final diagnosis. The 
morphology results were compared to the findings of the morphologist at the time of 
diagnosis.  All the results were only correlated at the end of the individual analyses. 
• The PANDA analysis grid also includes cases of MPO deficiency, AIDS, MDS and viral 
disease. Patients with these diseases were not included in the patient cohort as the focus 
of the study was the value of PANDA analysis in the classification of leukaemia. 
• This study did not explore whether the Advia printout can be used to distinguish normal 
peripheral blood samples from leukaemic samples, as the aim of the current study was to 
establish if leukaemia can be classified on analysis of the cytograms.  
• This study also illuminated some of the limitations of the current PANDA 
classification which includes the difficulties of sub classifying AML according to the 
FAB classification and differentiating ALL from AML without peroxidase activity. A 
revised cytogram classification grid is proposed (Table 5.1). 
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Chapter 5: CONCLUSION 
 
The timeous identification and classification of leukaemia is crucial for patient survival,  and 
is essential to prompt further investigations to confirm the diagnosis and to initiate treatment 
as soon as possible. The current system requires that a highly trained technologist identify the 
leukaemic infiltrate and then refer the smear to a pathologist for confirmation. The shortage of 
skilled and experienced morphologists in our setting especially in remote areas where 
pathologists  are not available  means that slides have to be transported to central laboratories 
for review. This leads to unnecessary diagnostic delays and may compromise patient outcome. 
The WBC cytograms from automated analysers can offer an effective, simple tool  that can be 
used by less skilled morphologists to aid in the classification of leukaemia.  
 
In this study it has been shown that the analysis of WBC cytograms in conjunction with 
morphology can improve the overall assessment of leukaemic cases by providing a provisional 
classification to the clinicians.  Furthermore cytogram analysis alone has the potential to 
differentiate myeloid from lymphoid malignancies, provide a surrogate for the Day 8 blast 
count and to identify specific malignancies such as  CML, APL and AML with definite 
peroxidase activity. In routine laboratory practice, amidst the many samples that are received, 
a  simple review of  cytograms of suspected leukaemia even before a slide is stained can alert 
the technologist/pathologist to a provisional diagnosis. Nonetheless it must be remembered 
that morphology is not a lost art as microscopic analysis of cases is essential as subtle 
morphology features are not appreciated by an automated analyser.  Adequate training of both 
technologists and pathologists in the interpretation of cytograms in conjunction with 
morphology is strongly advocated. 
 
Recommendations 
We propose a revised PANDA classification grid to classify leukaemias (Table 5.1).  
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Table 5.1: Revised PANDA classification grid for the classification of leukaemias 
 P0 P1/ P2/P3 P3/P4/P5 P6 
D0 • Acute lymphoblastic 
leukaemia 
• Chronic lymphoid 
• Leukaemia 
 • Chronic myeloid 
leukaemia 
 
D1 • Acute lymphoblastic 
leukaemia 
• Non-Hodgkin lymphoma 
• Peroxidase negative acute 
myeloid leukaemia 
Acute myeloid 
leukaemia with 
peroxidase activity 
• Acute myeloid 
leukaemia with 
peroxidase activity 
• Chronic myeloid 
leukaemia-blast 
crisis 
Acute 
promyelocytic 
leukaemia 
D2 • Consider acute leukaemia    
 
The proposed classification is simpler and is not aimed at specifying different subtypes of 
leukaemia, but is implied rather as a screening tool. The limitation of the revised grid is that 
the focus is only on leukaemias while the differential diagnosis on the original grid included 
MPO deficiency, viral disease, myelodysplastic syndrome and AIDS. This was not explored in 
this study, and provides opportunity for future studies.  In addition, the cytogram pattern for 
AML M3 variant was not assessed as no cases of this nature were collected during the study 
period, however a recent study that included four cases of FAB M3 variant revealed varying 
degrees of peroxidase activity. This study also confirmed the finding that cytograms can be 
used to identify a possible case of APL. Nonetheless, this proposed classification promptly 
alerts one to the provisional diagnosis of certain myeloid leukaemias and acute leukaemia. 
 
The sensitivity and specificity of the peroxidase cytogram in evaluating the presence or 
absence of MPO are 85% and 88.6% respectively.  It was shown that there is a high agreement 
between the ADVIA peroxidase cytogram interpretation and the reference methods (flow 
cytometry and cytochemistry).  The findings suggest that in order to save time and reduce 
laboratory costs assessment of MPO activity from the peroxidase cytogram can be used as a 
screening tool if the blast population is greater than 5%. 
 
The Day 8 blast count obtained from the ADVIA printout can possibly be used as a surrogate 
marker for prognosis in paediatric ALL especially in under-resourced health care facilities. 
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APPENDIX B: Raw data of discrepant results using PANDA 
analysis    
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